** Shares of Cyclopharm CYC.AX rise 6.6% to A$1.525, their highest level since February 27
** Radiopharmaceutical co says its signed a 5-year agreement with USA Veterans Administration
** The five-year Federal Supply Schedule $(FSS)$ agreement works to expand co's medical radioactive technology Technegas’ adoption within the US federal healthcare system
** Stock set for second straight session of gains
** CYC up 4.7% YTD
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。